FT-596

N/A

Report date: 2022/02/15 17:13:45

Base Information

Drug NameFT-596

Drug Alias NameFT-596

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy

Mechanisms of ActionAnti-CD19Low affinity immunoglobulin gamma Fc region receptor III-A agonists

TargetsB-lymphocyte antigen CD19Low affinity immunoglobulin gamma Fc region receptor III-A

Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[8]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesFate Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesMasonic Cancer Center, University Of Minnesota

Inactive CompaniesFate Therapeutics Inc

Active IndicationsLymphoma, Large B-Cell, DiffuseLymphoma, B-CellLymphoma, Non-Hodgkin

Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[5]

Other Information

ATC CodeN/A